Objectives-To assess the prevalence of antibodies to human fibronectin (anti-Fn) in sera of patients with certain connective tissue diseases and to determine their association with disease activity and the pattern of organ involvement in patients with systemic lupus erythematosus (SLE). 
(SLE).
Methods-A capture enzyme linked immunosorbent assay (ELISA) was developed to quantify anti-Fn antibodies in serum samples from 65 patients with well characterised SLE, 50 with rheumatoid arthritis (RA), 15 with Behcet's disease (BD), 15 with systemic vasculitis and 36 healthy subjects. An anti-Fn antibody titre greater than mean + 3SD of the healthy control log values after back transformation to the normal scale was considered positive. Disease activity in SLE patients was scored using the British Isles Lupus Assessment Group (BILAG) Index. Erythrocyte sedimentation rate (ESR), concentrations of anti-dsDNA antibody, soluble interleukin-2 receptors (sIL-2R), C3, C4, C3 degradation products (C3dg) and immunoglobulin, and antinuclear antibody (ANA) titres were measured in blood samples from SLE patients; neopterin concentration was measured in corresponding urine samples. Results-Anti-Fn antibodies were found in 22 of 65 SLE patients (33.8%), seven of 50 with RA (14%), one of 15 with BD (6.6%) and none of the 15 subjects with vasculitis. Thirty SLE patients had active disease and 35 had inactive disease; their median anti-Fn concentrations were 117 u/ml (range 47-450) and 68 u/ml (range 17-334), respectively (p = 0.0001). The presence of anti-Fn did not correlate with immunoglobulin concentrations or ANA titres in these sera. No significant difference was found between SLE patients with disease activity in one major organ system compared with multiple organ involvement, as defined by BILAG (p = 0 19). However, patients with musculoskeletal manifestations had consistently greater anti-Fn concentrations compared with patients with other clinical manifestations. There were significant correlations between amounts of anti-Fn in SLE sera and ESR (r, = 0.25, p = 0 045), sIL-2R (r,= 0-28, p 0-024) and urine neopterin (r, = 0-3, p = 0-016) but not with serum anti-dsDNA antibody titres, plasma C3, C3dg or C4. However multiple regression analysis showed a low significant correlation only with sIL-2R and BILAG score (p = 0 047 and 0-042, respectively). Conclusion-Anti-Fn antibodies were detected in 34% of SLE patients and in small proportions of RA and BD patients. An association between serum anti-Fn and disease activity in SLE has been identified and most SLE patients with musculoskeletal involvement had increased anti-Fn antibody concentrations. We developed a capture enzyme linked immunosorbent assay (ELISA) to measure anti-human Fn antibody concentrations to assess their prevalence in certain connective tissue diseases and possible clinical relevance. In SLE, their association with patterns of organ involvement and disease activity was ascertained.
Patients and methods

PATIENTS
Sixty five patients fulfilling at least four of the 1982 revised American Rheumatology Association criteria'0 for the classification of SLE were studied. There were 62 females and three males, with a mean age of 42-9 (SD 12-6) years. The computerised British Isles Lupus Assessment Group (BILAG) index of disease activity was used to assess lupus activity" in the major organ systems (mucocutaneous, nervous, musculoskeletal, cardiovascular, vasculitis, renal, and haematological) and general constitutional manifestations. All the organ systems were graded A to E and BILAG scores of 9, 3, 1, 0 and 0 were considered to correspond grades A, B, C, D, and E, respectively. Any system graded A or B was considered to display active disease. The overall BILAG score for an individual patient was the sum of the disease activity scores in the eight systems assessed.
The control groups consisted of 36 healthy subjects (mean age 42-1 (12) 0.1% Tween 20 (PBS-T) for one hour. All incubation steps were carried out at room temperature with gentle agitation. Strips of the membrane were incubated for 18 hours with rabbit anti-human Fn antiserum (The Binding Site) diluted 1: 100, mouse anti-human Fn monoclonal antibody (Sigma) diluted 1:100, or a representative human serum known to contain anti-Fn antibodies2 diluted 1:50. All sera were diluted in 5% BSA in PBS-T. The strips were then washed for 30 minutes with PBS-T, followed by a four hour incubation with horseradish peroxidase labelled goat antirabbit IgG (BioRad), goat anti-mouse IgG (Sigma) or goat anti-human immunoglobulin y and p. chain specific (Sigma). The strips were washed as above and bound antibodies were detected using the substrate chromogen 4-chloro-1-naphthol (Sigma).
ASSAY FOR ANTI-FN ANTIBODIES
A capture ELISA was used for quantitative determination of anti-Fn antibody concentrations. Mouse monoclonal anti-human Fn antibody was used to capture Fn from the commercial preparation. The mouse antihuman Fn monoclonal antibody was added to carbonate-bicarbonate buffer (pH 9 6), to a final dilution of 1:2000 and 50 pl aliquots were incubated on wells of microtitre plates (Maxisorp, Nunc) for five hours. All incubations were carried out at room temperature. The wells were then washed three times with 120 p.1 of PBS-T. Residual binding sites were blocked with 75 p.l of 2% BSA for two hours. After aspiration of the BSA solution, 50 pl. of the Fn (Sigma) in PBS-T (5 ,ug/ml) was added to each well and the plates were incubated for 18 hours. The wells were washed again and 50 p.l of human sera diluted 1:20 in PBS-T was added to duplicate wells. The plates were incubated for two hours. After three washes, 50 ,ul of alkaline phosphatase labelled goat antihuman immunoglobulin ot, ry and p. chain specific (Sigma) were added to all wells and the plates incubated for one hour at room temperature. The wells were washed again and the bound reactant detected by incubation with 50 p1/well of 1 mg/ml p-nitrophenyl phosphate disodium (Sigma) in diethanolamine buffer pH 9 6. The optical density (OD) of the colour developed was measured after 30 minutes using a Dynatech MR500 ELISA reader.
The following controls were included with each assay: (1) Control for non-specific binding (wells blocked with BSA without prior coating with the monoclonal anti-Fn or Fn to which the sera were added in duplicate). The OD of nonspecific binding for each sample was subtracted from the OD of sample binding to Fn coated wells, and the absolute values were used to calculate anti-Fn concentrations. (2) Anti-Fn antibody concentrations in SLE patients with or without antibodies to Ro or La antigens were also studied. Antibodies to the former antigen were detected in 17 of 65 patients with SLE and antibodies to the latter were present in 20 of the 65. Concentrations of anti-Fn antibodies in the SLE group with Ro antibodies (median 81, interquartile range 100-5-301-5 u/ml) were not significantly different (p = 0-7) from those without the Ro antibodies (median 72, interquartile range 104-5-314-2 u/ml). No significant difference (p = 0 6) was observed between anti-Fn antibody concentrations in SLE patients with anti-La antibodies (median 43-6, interquartile range 100-5-301-5 u/ml) and those without anti-La antibodies (median 76-5, interquartile range 104-7-314-2 u/ml).
ASSOCIATION OF ANTI-EN ANTIBODIES WITH SLE
TREATMENT
Fourteen SLE patients were receiving cytotoxic drugs, 21 were taking prednisolone, 14 were receiving both, and 16 were receiving hydroxychloroquine or no treatment. The median (interquartile range) anti-Fn antibody concentrations in these groups were 103 (83 2-249 8) u/ml, 83 (97-2-291-8) u/ml, and 84 (100-400) u/ml, respectively. No significant differences in anti-Fn antibody concentrations were found between these groups using the Kruskall-Wallis H test (p = 0 28). An attempt was also made to follow anti-Fn antibody concentrations in seven SLE patients when their BILAG disease activity index changed, during two consecutive assessments, from active to inactive or vice versa. range 89-8-269-2) were not significantly different from those in 20 patients with single system involvement (median 106 u/ml, interquartile range 108-2-324-2) (p = 0 19).
Eight of the 11 patients with active musculoskeletal system involvement (arthritis, myositis, tendonitis, arthralgia, and myalgia) had increased anti-Fn antibodies. Five of these eight patients had other organ systems actively involved: three had haematological abnormalities (anaemia, leucopenia, lymphopenia and thrombocytopenia), one had cutaneous manifestation (alopecia) and cutaneous vasculitis, and one had active renal disease. Such a possibility accords with our previous in vitro experiments which showed that anti-Fn antibodies from SLE sera can influence interactions involving the extracellular matrix and cells,6 and with our observation that patients' anti-Fn antibodies have a high affinity for Fn which is comparable to that of anti-Fn antibodies from hyperimmune animals (unpublished data). Alternatively, the presence of the anti-Fn antibodies may be a consequence of the immunological process and could be involved in the perpetuation of the disease process.
The presence of autoantibodies in active SLE has been suggested to be a consequence of polyclonal B cell activation,'9 antigen driven B cell activation'O 21 or a combination of both mechanisms.22 As the increase in anti-Fn concentrations did not correlate with immunoglobulin concentrations (IgG, IgM or IgA) or the titre of ANA antibodies and was not associated with Ro or La autoantibodies, selective B cell activation by Fn, rather than a non-specific polyclonal activation, is more likely.
SLE is clinically and serologically a heterogeneous condition. Certain antibodies have been linked to particular clinical manifestations of SLE-for example anti-dsDNA and renal disease.23 In the analysis involving matching the presence of anti-Fn antibodies with particular clinical manifestations, with the exception of the musculoskeletal system there was broadly similar disease activity in SLE patients with and without increased serum anti-Fn antibody concentrations in the eight systems assessed. Although, on clinical grounds, most patients (eight of 11) with musculoskeletal involvement had increased serum antibodies to human Fn, it is not possible to delineate a subset of SLE patients. It is also worth noting that anti-Fn antibodies were present in all three patients with active renal disease and none of the three patients with active neurological disease. This might suggest that anti-Fn antibodies have a role in immune complex mediated mechanisms which occur in SLE. A serial assessment of a larger number of patients which included monitoring of anti-Fn concentrations would be required to ascertain such associations.
In conclusion, we have developed a capture ELISA to measure anti-Fn antibodies in human sera. The antibodies were detected in 34%/o of SLE patients and in a small proportion of RA patients. The concentrations of the antibody were significantly greater in the SLE patients with active disease, and were significantly correlated with ESR, sIL-2R, and urine neopterin values. Patients with anti-Fn had more active disease as indicated by laboratory indices of disease activity. Most patients with active musculoskeletal manifestations were anti-Fn antibody positive.
